Detailed Information

Cited 13 time in webofscience Cited 15 time in scopus
Metadata Downloads

Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment

Authors
Lee, YSJoe, KHSohn, IKNa, CKee, BSChae, SL
Issue Date
Jun-2005
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Keywords
endogenous opioid; hypothalamo-pituitary-adrenocortical axis; naltrexone; nicotine dependence
Citation
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.29, no.5, pp 639 - 647
Pages
9
Journal Title
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Volume
29
Number
5
Start Page
639
End Page
647
URI
https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/24588
DOI
10.1016/j.pnpbp.2005.04.008
ISSN
0278-5846
1878-4216
Abstract
This study was done to evaluate the therapeutic effects of naltrexone on smoking behaviors and to measure the changing of brain substances for elucidating the mode of action by naltrexone. Twenty-five voluntarily participated healthy male smokers were randomly assigned to naltrexone group or placebo group for 2 weeks. In this study, naltrexone group showed significant reduction in daily cigarette consumption amount, the expiratory CO levels, brief questionnaire for smoking urge (B-QSU) score, and FTQ score. However, only 2 subjects in naltrexone group quitted smoking completely at 4th week. Plasma levels of pituitary hormones (ACTH, cortisol, and prolactin) and endogenous opioids (beta-endorphin and dynorphin A) were checked weekly before and after the 'provocation and smoking coupled' stimulus once in a week for 3 weeks. In naltrexone group, pituitary hormones showed upward tendencies even though only the prolactin had statistical significance. However, P-endorphin and dynorphin A were not significantly different between the two groups. It was suggested that naltrexone made effects on hypothalamo -pituitary - adrenocortical axis activity as well as smoking behavior. However, the meaning of these endocrinal changes by naltrexone is not conclusive, whether it is beneficial or aversive. (C) 2005 Elsevier Inc. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > College of Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE